Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
03/23/2020 03/24/2020 03/25/2020 03/26/2020 03/27/2020 Date
1450 1520 1657 1595.5 1724.5 Last
15668900 11845100 8247000 7377400 10300700 Volume
-2.78% +4.83% +9.01% -3.71% +8.09% Change
Financials (JPY)
Sales 2020 1 275 B
EBIT 2020 257 B
Net income 2020 204 B
Finance 2020 458 B
Yield 2020 2,37%
Sales 2021 1 278 B
EBIT 2021 264 B
Net income 2021 208 B
Finance 2021 579 B
Yield 2021 2,52%
P/E ratio 2020 15,3x
P/E ratio 2021 15,3x
EV / Sales2020 2,15x
EV / Sales2021 2,06x
Capitalization 3 205 B
More Financials
Company
Astellas Pharma specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (31.2%), Asia... 
More about the company
Surperformance© ratings of Astellas Pharma Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTELLAS PHARMA INC.
03/24CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop ..
AQ
03/23ASTELLAS PHARMA : CytomX Therapeutics and Astellas Announce Strategic Collaborat..
PU
03/18ASTELLAS PHARMA : Gifu University and Astellas establish a Research Course on Ph..
AQ
02/27ASTELLAS PHARMA : Notice Regarding the Performance-linked Stock Compensation Sch..
PU
02/20Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation fo..
AQ
02/19ASTELLAS PHARMA : and Seattle Genetics Receive FDA Breakthrough Therapy Designat..
PU
02/12ASTELLAS PHARMA : XTANDI Demonstrates Significant Improvement in Overall Surviva..
AQ
02/11SEATTLE GENETICS : and Astellas Announce Updated Results from Phase 1b/2 Trial o..
AQ
02/06ASTELLAS PHARMA : Announces Management Structure
AQ
02/03ASTELLAS PHARMA : Announces Completion of Acquisition of Own Shares, and Cancell..
PU
01/31ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Evre..
AQ
01/31Astellas Pharma keeps profit forecast as prostate cancer drug sales rise
RE
01/31ASTELLAS PHARMA : Will Renew Its Corporate Website's Innovation Section
PU
01/28ASTELLAS PHARMA INC. : quaterly earnings release
01/23ASTELLAS PHARMA : Amgen astellas biopharma to become a wholly owned amgen affili..
PU
More news
News in other languages on ASTELLAS PHARMA INC.
03/05Les Bourses asiatiques terminent en nette hausse, imitant Wall Street
03/05Tokyo finit en hausse, dopée par Wall Street
03/04Tokyo en nette hausse, dans le sillage de Wall Street
02/25Tokyo dévisse de 3,3% en clôture, le coronavirus inquiète
02/24TOKYO : le Nikkei chute de 4% à l'ouverture à cause du coronavirus
More news
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 2 129,17  JPY
Last Close Price 1 724,50  JPY
Spread / Highest target 68,2%
Spread / Average Target 23,5%
Spread / Lowest Target -13,0%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Senior Executive Officer & Head-Finance
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.2.70%29 657
JOHNSON & JOHNSON-13.23%324 693
ROCHE HOLDING AG-5.29%264 026
MERCK & CO., INC-21.13%181 927
NOVARTIS-16.30%180 007
PFIZER, INC.-21.13%171 422